以上新产品医疗器械注册证的取得，丰富了公司产品线，将对公司业务发展 具有正面影响。公司目前尚无法预测上述产品对公司未来营业收入的影响，敬请 投资者给予关注并注意投资风险。 关于产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，上海科华生物工程股份有限公司（以下简称"公司"）控股子公司西 安天隆科技有限公司收到国家药品监督管理局颁发的医疗器械注册证。具体情况 如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期 | 适用范围/预期用途 产品基于实时荧光PCR检 | | --- | --- | --- | --- | --- | | 1 | 实时荧光定量 | 国械注准 | 2026年2月12日 至 | 测原理，与配套的检测试 剂共同使用，在临床上用 于对来源于人体样本中的 | | | PCR仪 | 20263220324 | 2031年2月11日 | 靶核酸（DNA/RNA）进行定 | | | | | | 性、定量检测，包括病原 | | | | | | 体和人类基因检测项目。 | | 证券代码：002022 | 证券简 ...

证券代码：002022 证券简称：科华生物 公告编号：2026-008 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 关于不向下修正"科华转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、截至 2026 年 3 月 9 日，上海科华生物工程股份有限公司（以下简称"公司"） 股票已出现在任意连续 20 个交易日中至少有 10 个交易日的收盘价低于当期转股价 格的 90%的情形，已触发"科华转债"转股价格的向下修正条款。 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准上海科华生 物工程股份有限公司公开发行可转换公司债券的批复》（证监许可［2020］970 号） 核准，公司于 2020 年 7 月 28 日公开发行了 738.00 万张可转换公司债券，每张面值 100 元，发行总额 73,800.00 万元。经深圳证券交易所（以下简称"深交所"）"深 证上[2020]731 号"文同意，公司 73,800.00 万元可转债于 2020 年 8 月 20 日起在 深交所挂牌交易，债券简称"科 ...

证券代码：002022 证券简称：科华生物 公告编号：2026-009 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 关于 2026 年度向金融机构融资和为子公司提供担保的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、公司向金融机构融资 （一）金融机构融资额度 公司及子公司2026年度计划以信用、抵押、质押、担保等形式向金融机构申 请新增/延续合计总额不超过人民币100,000万元(含本数)的融资额度，用于包括 但不限于短期流动资金贷款、贸易融资、银行承兑汇票、商业承兑汇票、贴现、 保函、信用证、融资租赁、保理等业务，具体业务品种、融资额度和期限以公司 及子公司与金融机构最终签署的相关借款合同或协议为准。上述融资额度有效期 限自前次融资额度的授权到期之日起12个月内（即2026年3月21日至2027年3月20 日），融资额度为公司及子公司共同使用，在期限内可循环使用。 公司及子公司拟为上述融资中的部分融资业务提供担保，担保额不超过人民 币20,000万元（含本数，包括公司对子公司的担保、子公司之间的担保等）。 （二）并 ...

| 证券代码:002022 | | --- | | 债券代码:128124 | 证券代码：002022 证券简称：科华生物 公告编号：2026-007 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 第十届董事会第十九次会议决议公告 具体详见公司于同日在《证券时报》《中国证券报》《上海证券报》及巨潮 资讯网（http://www.cninfo.com.cn）披露的《关于不向下修正"科华转债"转 股价格的公告》（公告编号：2026-008）。 表决结果：同意9票，反对0票，弃权0票。 （二）审议通过《关于 2026 年度向金融机构融资和为子公司提供担保的议 案》 公司董事会同意公司及全资、控股子公司（均为合并报表范围内的子公司， 以下统称"子公司"）向金融机构申请不超过人民币 100,000 万元(含本数)的融 资额度及人民币 80,000 万元（含本数）的并购和项目贷款融资额度，并为资产 负债率 70%以下的子公司提供担保总额不超过人民币 20,000 万元（含本数）的 连带责任担保。 本次融资和担保事项系为满足公司及子公司生产经营和业务发展需要，符合 公司的整体利益。本次担保事项符 ...

证券代码：002022 证券简称：科华生物 公告编号：2026-006 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 关于"科华转债"预计触发 转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： （一）基本情况 经中国证券监督管理委员会（以下简称"证监会"）《关于核准上海科华生物 工程股份有限公司公开发行可转换公司债券的批复》（证监许可［2020］970 号） 1、证券代码：002022 证券简称：科华生物 2、债券代码：128124 债券简称：科华转债 3、转股价格：人民币 20.64 元/股 核准，公司于 2020 年 7 月 28 日公开发行了 738.00 万张可转换公司债券，每张 面值 100 元，发行总额 73,800.00 万元。经深圳证券交易所"深证上[2020]731 号"文同意，公司 73,800.00 万元可转债于 2020 年 8 月 20 日起在深圳证券交易 所挂牌交易，债券简称"科华转债"，债券代码"128124"。 （二）可转债转股期限 根据相关法律法规和《募集 ...

Core Viewpoint - The diagnostic reagent industry in China is experiencing fluctuations in market size due to the impact of COVID-19, with a projected recovery and growth expected by 2025, reaching a market size of 140 billion yuan, an 8% increase year-on-year [6][7]. Industry Overview - Diagnostic reagents are essential tools in medicine and biology for detecting diseases, infections, and other medical conditions through interactions with biological samples [4][6]. - The market is primarily dominated by in vitro diagnostic reagents, while in vivo diagnostics remain relatively small [6]. Market Size and Trends - The market for in vitro diagnostic reagents in China has shown an upward trend since 2015, with rapid growth from 2020 to 2022 due to the pandemic, but a 14% decline in 2023 due to reduced demand for COVID-19 diagnostic reagents [6][7]. - The market is expected to recover in 2024, with projections indicating a market size of 140 billion yuan by 2025, reflecting an 8% year-on-year growth [6][7]. Competitive Landscape - The diagnostic reagent market includes both domestic companies like Mindray Medical, Antu Bio, and Wanfu Bio, and international firms such as Roche Diagnostics and Abbott, all competing for market share [8]. - Domestic companies are noted for their strong R&D capabilities and significant market presence [8]. Industry Development Stages - The diagnostic reagent industry in China has progressed through four stages: nascent, initial, extensive development, and rapid growth, with significant advancements in technology and regulatory improvements since the 21st century [5]. Industry Chain - The industry chain consists of upstream raw materials (diagnostic enzymes, antigens, antibodies, etc.), the midstream diagnostic reagent production, and downstream applications in medical institutions and third-party diagnostic organizations [6]. Market Segmentation - The in vitro diagnostic reagent market is segmented, with immunodiagnostic reagents holding a 32% market share, followed by molecular diagnostic reagents at 19%, and biochemical diagnostic reagents at 18% [7]. Future Trends - The industry is expected to focus on high-end product upgrades, with companies increasing R&D investments to enhance product value amidst price pressures from centralized procurement [9]. - There is a trend towards market penetration in lower-tier cities and global expansion, with domestic products entering emerging markets in Southeast Asia and Africa [10]. - The industry is evolving towards a model centered on clinical value and personalized medicine, integrating diagnostic solutions with treatment recommendations [11].

声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 有投资者在互动平台向科华生物提问："近期中国国际医疗设备与器械交易（集采）平台在天津市揭牌 上线，将推动实现医疗设备与器械'全球买、全球卖'，贵司是否有关注，是否考虑通过该平台推广销售 公司产品。" 针对上述提问，科华生物回应称："尊敬的投资者，您好！公司会密切关注行业发展趋势和市场需求， 结合公司实际业务需要和发展战略，制定业务规划，积极把握业务机会。同时，公司会不断完善国内外 销售渠道和服务渠道，积极拓展国内外市场。感谢您的关注！" ...

Core Viewpoint - The company, Kehua Bio-engineering, disclosed its construction in progress balance as of June 30, 2025, amounting to 1,640,045.17 yuan, which includes renovation and miscellaneous projects [1]. Group 1 - The company responded to investor inquiries on its interactive platform regarding its financial status [1]. - The balance of construction in progress is detailed in the company's semi-annual report for 2025 [1].

Core Insights - The digital PCR (dPCR) technology is emerging as a significant advancement in nucleic acid detection, providing more precise and sensitive methods for quantitative analysis, addressing limitations of traditional PCR methods [1][10] - The Chinese digital PCR market is projected to grow from 1.584 billion yuan in 2019 to 8.815 billion yuan by 2025, with a compound annual growth rate (CAGR) of 33.1% [1][10] - The growth is driven by technological advantages and supportive national policies, with increasing recognition of its value among researchers and clinicians [1][10] Industry Overview - Digital PCR is categorized into droplet digital PCR (ddPCR) and chip digital PCR (cdPCR), allowing for absolute quantification without relying on standard curves, suitable for single-cell analysis and early cancer diagnosis [3][4] - The technology offers significant advantages over traditional PCR, including higher sensitivity, accuracy, and better tolerance to complex samples [4][5] Market Dynamics - The digital PCR industry is supported by a robust supply chain, with upstream components including essential biological materials and core parts like optical and fluid control components [6] - The midstream involves the research, production, and sales of digital PCR devices, with notable domestic companies like New Yi Biological and Zhenzhun Biological emerging as competitors [6][7] Application Areas - Digital PCR is utilized in various fields, including clinical diagnostics for pathogen detection, research for gene expression analysis, food safety testing, and agricultural applications [7][8] - In clinical settings, it plays a crucial role in early disease diagnosis and monitoring, particularly in oncology and infectious diseases [8] Competitive Landscape - The digital PCR market in China has seen the emergence of several domestic companies, with 16 manufacturers winning bids in 2024, of which 11 are local brands [12][12] - New Yi Biological and Linghang Gene lead in market share, with respective bid shares of 20% and 17.14% [12] Future Trends - Continuous technological innovation is expected to enhance detection efficiency and reduce costs, with advancements in multi-color fluorescence detection and microfluidic chip technology [16][17] - Collaboration among upstream suppliers, midstream manufacturers, and downstream application sectors will foster a synergistic development environment [17] - There is a growing focus on expanding into international markets, with domestic companies aiming to enhance their global presence and competitiveness [18][19]

Core Viewpoint - The article analyzes the 2025 performance forecasts of 22 domestic listed instrument companies, highlighting the divergence in performance and the impact of various market factors on the industry [2]. Group 1: Industry Overview - The overall operating conditions of the domestic instrument industry are gradually becoming clearer as companies disclose their 2025 performance forecasts [2]. - Among the 22 companies, 11 reported profits while 11 incurred losses; 8 of the profitable companies experienced year-on-year growth, while 3 saw stable or slightly fluctuating profits [2]. - The performance divergence is attributed to factors such as fluctuations in downstream demand, intensified industry competition, policy changes, and global supply chain instability [2]. Group 2: Performance Statistics - The net profit statistics for the listed instrument companies indicate significant growth for several firms, with some achieving over 190% year-on-year increases [3][8]. - Notable performers include: - Aiko Optoelectronics: Net profit of 0.57-0.7 billion, up 262.52-345.20% from 0.1572 billion [3]. - Haineng Technology: Net profit of 0.41-0.44 billion, up 213.65-236.61% from 0.1307 billion [3]. - Wan Yi Technology: Net profit of 0.42-0.62 billion, up 191.52-330.34% from 0.1441 billion [3]. Group 3: Industry Trends - The industry is witnessing increased performance divergence, with a trend towards higher concentration as companies with core technologies and strategic layouts capture more market share [5]. - The ongoing domestic substitution is deepening, with high-end instruments becoming a key growth driver, supported by policy incentives for high-end scientific instruments and equipment upgrades [5]. - Companies focusing on high-end sectors, such as high-end industrial imaging and clinical diagnostics, are expected to benefit from these trends [5]. Group 4: Operational Strategies - Companies facing operational pressures are likely to improve performance by divesting loss-making businesses, optimizing asset structures, and enhancing management of receivables and inventory [6]. - Profit-making companies will continue to pursue refined management practices to consolidate their advantages and enhance risk resilience [6]. Group 5: Performance Categories - Companies achieving profit growth or turning losses into profits are primarily benefiting from asset impairment improvements and business structure optimizations [18]. - The companies in this category include: - Gaode Infrared: Successfully turned around from a loss to a profit [18]. - Xianhe Environmental: Achieved profitability through structural optimization [21]. - Zhengye Technology: Also turned from loss to profit due to similar improvements [22]. Group 6: Challenges Faced - Companies experiencing expanded losses or transitioning from profit to loss share common challenges, including reliance on single business lines and significant asset impairment pressures [30]. - The need for transformation is evident, as some companies are in the process of adjusting their business models, which may not yet yield sufficient revenue to offset declines in traditional business areas [30].